A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis is poor and more than three quarters of patients experience progression 12 months after the initiation of conventional first-line chemotherapy. Approximately two thirds of TNBC expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamot, Christoph, Wicki, Andreas, Hasler-Strub, Ursula, Riniker, Salome, Li, Qiyu, Holer, Lisa, Bärtschi, Daniela, Zaman, Khalil, von Moos, Roger, Dedes, Konstantin J., Boos, Laura A., Novak, Urban, Bodmer, Alexandre, Ritschard, Reto, Obermann, Ellen C., Tzankov, Alexandar, Ackermann, Christoph, Membrez-Antonioli, Véronique, Zürrer-Härdi, Ursina, Caspar, Clemens B., Deuster, Stefanie, Senn, Martin, Winterhalder, Ralph, Rochlitz, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988854/
https://www.ncbi.nlm.nih.gov/pubmed/36879012
http://dx.doi.org/10.1038/s41598-023-30950-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988854/
https://www.ncbi.nlm.nih.gov/pubmed/36879012
http://dx.doi.org/10.1038/s41598-023-30950-z

Ejemplares similares